Savant Capital LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,517 shares of the company’s stock, valued at approximately $244,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of AZN. ICA Group Wealth Management LLC bought a new position in shares of AstraZeneca during the fourth quarter worth $26,000. Parkside Financial Bank & Trust raised its holdings in shares of AstraZeneca by 4,875.0% during the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock worth $26,000 after acquiring an additional 390 shares during the period. Fairfield Bush & CO. acquired a new stake in shares of AstraZeneca during the first quarter worth $28,000. Red Tortoise LLC acquired a new stake in shares of AstraZeneca during the fourth quarter worth $30,000. Finally, Byrne Asset Management LLC increased its stake in AstraZeneca by 55.0% in the 4th quarter. Byrne Asset Management LLC now owns 465 shares of the company’s stock valued at $32,000 after buying an additional 165 shares during the last quarter. 16.07% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on AZN shares. HSBC started coverage on shares of AstraZeneca in a research note on Friday, July 14th. They issued a “buy” rating on the stock. Argus lowered their price target on shares of AstraZeneca from $85.00 to $80.00 in a research note on Friday, May 26th. Morgan Stanley upgraded shares of AstraZeneca from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, April 11th. StockNews.com assumed coverage on shares of AstraZeneca in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. Finally, UBS Group upgraded shares of AstraZeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $103.00.
AstraZeneca Stock Performance
AstraZeneca (NASDAQ:AZN – Get Free Report) last posted its quarterly earnings data on Friday, July 28th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.97 by $0.11. The firm had revenue of $11.42 billion during the quarter, compared to the consensus estimate of $11.06 billion. AstraZeneca had a net margin of 10.73% and a return on equity of 28.86%. Analysts anticipate that AstraZeneca PLC will post 3.64 earnings per share for the current year.
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
See Also
- Five stocks we like better than AstraZeneca
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 7/24 – 7/28
- What Are MATANA Stocks?
- Can SAIA Continue its Stratospheric Rally?
- How to Invest in Growth Stocks
- Why Markets Are Loving Exxon Mobil, Despite The Earnings Dip
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
